Latest Insider Transactions at Elevance Health, Inc. (ELV)
This section provides a real-time view of insider transactions for Elevance Health, Inc. (ELV). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Elevance Health, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Elevance Health, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 01
2024
|
Peter D Haytaian EVP & Pres Carelon & CarelonRx |
BUY
Grant, award, or other acquisition
|
Direct |
3,799
+15.3%
|
-
|
|
Nov 01
2024
|
Peter D Haytaian EVP & Pres Carelon & CarelonRx |
SELL
Payment of exercise price or tax liability
|
Direct |
1,649
-8.73%
|
$682,686
$414.01 P/Share
|
|
Nov 01
2024
|
Charles Morgan Kendrick Jr EVP & President, Commercial |
BUY
Grant, award, or other acquisition
|
Direct |
1,710
+15.55%
|
-
|
|
Nov 01
2024
|
Charles Morgan Kendrick Jr EVP & President, Commercial |
SELL
Payment of exercise price or tax liability
|
Direct |
846
-10.04%
|
$350,244
$414.01 P/Share
|
|
Oct 18
2024
|
Charles Morgan Kendrick Jr EVP & President, Commercial |
SELL
Open market or private sale
|
Direct |
7,417
-46.82%
|
$3,204,144
$432.14 P/Share
|
|
Oct 02
2024
|
Mark Kaye EVP & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,818
-12.24%
|
$1,423,090
$505.16 P/Share
|
|
Aug 05
2024
|
Ramiro G Peru Director |
SELL
Open market or private sale
|
Direct |
753
-7.93%
|
$399,843
$531.52 P/Share
|
|
Jul 22
2024
|
Gail Boudreaux President and CEO |
SELL
Open market or private sale
|
Direct |
34,000
-3.78%
|
$17,034,000
$501.74 P/Share
|
|
Jul 19
2024
|
Robert L Dixon Jr Director |
SELL
Open market or private sale
|
Direct |
305
-3.04%
|
$154,330
$506.76 P/Share
|
|
May 15
2024
|
Ramiro G Peru Director |
BUY
Grant, award, or other acquisition
|
Direct |
388
+3.93%
|
-
|
|
May 15
2024
|
Ryan M. Schneider Director |
BUY
Grant, award, or other acquisition
|
Direct |
388
+6.07%
|
-
|
|
May 15
2024
|
Deanna D Strable Soethout Director |
BUY
Grant, award, or other acquisition
|
Direct |
388
+27.08%
|
-
|
|
May 15
2024
|
Elizabeth E Tallett Director |
BUY
Grant, award, or other acquisition
|
Direct |
388
+3.63%
|
-
|
|
May 15
2024
|
Susan D. De Vore Director |
BUY
Grant, award, or other acquisition
|
Direct |
388
+18.57%
|
-
|
|
May 15
2024
|
Robert L Dixon Jr Director |
BUY
Grant, award, or other acquisition
|
Direct |
388
+3.73%
|
-
|
|
May 15
2024
|
Lewis Hay Iii Director |
BUY
Grant, award, or other acquisition
|
Direct |
388
+3.44%
|
-
|
|
May 15
2024
|
Bahija Jallal Director |
BUY
Grant, award, or other acquisition
|
Direct |
388
+8.48%
|
-
|
|
May 15
2024
|
Antonio F Neri Director |
BUY
Grant, award, or other acquisition
|
Direct |
388
+8.23%
|
-
|
|
May 15
2024
|
R Kerry Clark Director |
BUY
Grant, award, or other acquisition
|
Direct |
388
+4.12%
|
-
|
|
Apr 24
2024
|
Felicia F Norwood EVP & President,Gov Health Ben |
SELL
Open market or private sale
|
Direct |
6,199
-9.71%
|
$3,297,868
$532.41 P/Share
|
|
Apr 24
2024
|
Felicia F Norwood EVP & President,Gov Health Ben |
BUY
Exercise of conversion of derivative security
|
Direct |
2,043
+5.75%
|
$486,234
$238.27 P/Share
|
|
Apr 23
2024
|
Felicia F Norwood EVP & President,Gov Health Ben |
SELL
Open market or private sale
|
Direct |
14,111
-15.53%
|
$7,535,274
$534.23 P/Share
|
|
Apr 23
2024
|
Felicia F Norwood EVP & President,Gov Health Ben |
BUY
Exercise of conversion of derivative security
|
Direct |
5,473
+10.72%
|
$1,302,574
$238.27 P/Share
|
|
Mar 08
2024
|
Charles Morgan Kendrick Jr EVP & President, Commercial |
SELL
Open market or private sale
|
Direct |
2,432
-13.31%
|
$1,216,000
$500.46 P/Share
|
|
Mar 06
2024
|
Ronald W Penczek CAO & Controller |
SELL
Open market or private sale
|
Direct |
916
-34.18%
|
$461,664
$504.58 P/Share
|
|
Mar 04
2024
|
Peter D Haytaian EVP & Pres Carelon & CarelonRx |
SELL
Open market or private sale
|
Direct |
21,095
-20.02%
|
$10,547,500
$500.18 P/Share
|
|
Mar 04
2024
|
Peter D Haytaian EVP & Pres Carelon & CarelonRx |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+27.28%
|
$2,490,000
$166.97 P/Share
|
|
Mar 01
2024
|
Blair Williams Todt EVP, CLO & CAO |
BUY
Grant, award, or other acquisition
|
Direct |
8,691
+22.23%
|
-
|
|
Mar 01
2024
|
Blair Williams Todt EVP, CLO & CAO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,650
-30.13%
|
$1,821,350
$499.11 P/Share
|
|
Mar 01
2024
|
Ronald W Penczek CAO & Controller |
BUY
Grant, award, or other acquisition
|
Direct |
1,272
+20.11%
|
-
|
|
Mar 01
2024
|
Ronald W Penczek CAO & Controller |
SELL
Payment of exercise price or tax liability
|
Direct |
383
-21.38%
|
$191,117
$499.11 P/Share
|
|
Mar 01
2024
|
Peter D Haytaian EVP & Pres Carelon & CarelonRx |
BUY
Grant, award, or other acquisition
|
Direct |
11,557
+20.0%
|
-
|
|
Mar 01
2024
|
Peter D Haytaian EVP & Pres Carelon & CarelonRx |
SELL
Payment of exercise price or tax liability
|
Direct |
4,314
-24.32%
|
$2,152,686
$499.11 P/Share
|
|
Mar 01
2024
|
Felicia F Norwood EVP & President,Gov Health Ben |
BUY
Grant, award, or other acquisition
|
Direct |
11,557
+12.9%
|
-
|
|
Mar 01
2024
|
Felicia F Norwood EVP & President,Gov Health Ben |
SELL
Payment of exercise price or tax liability
|
Direct |
4,902
-14.66%
|
$2,446,098
$499.11 P/Share
|
|
Mar 01
2024
|
Charles Morgan Kendrick Jr EVP & President, Commercial |
BUY
Grant, award, or other acquisition
|
Direct |
4,508
+11.67%
|
-
|
|
Mar 01
2024
|
Charles Morgan Kendrick Jr EVP & President, Commercial |
SELL
Payment of exercise price or tax liability
|
Direct |
1,484
-9.73%
|
$740,516
$499.11 P/Share
|
|
Mar 01
2024
|
Ratnakar Lavu EVP & Chief Digital Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,756
+38.33%
|
-
|
|
Mar 01
2024
|
Gail Boudreaux President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
42,932
+11.97%
|
-
|
|
Mar 01
2024
|
Gail Boudreaux President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
19,256
-14.05%
|
$9,608,744
$499.11 P/Share
|
|
Mar 01
2024
|
Mark Kaye EVP & CFO |
BUY
Grant, award, or other acquisition
|
Direct |
2,755
+10.68%
|
-
|
|
Feb 07
2024
|
Ramiro G Peru Director |
SELL
Open market or private sale
|
Direct |
753
-7.64%
|
$376,500
$500.0 P/Share
|
|
Jan 03
2024
|
Blair Williams Todt EVP, CLO & CAO |
SELL
Payment of exercise price or tax liability
|
Direct |
397
-3.17%
|
$190,560
$480.49 P/Share
|
|
Dec 14
2023
|
Blair Williams Todt EVP, CLO & CAO |
SELL
Open market or private sale
|
Direct |
5,492
-30.5%
|
$2,658,128
$484.02 P/Share
|
|
Dec 14
2023
|
Blair Williams Todt EVP, CLO & CAO |
BUY
Exercise of conversion of derivative security
|
Direct |
5,492
+23.37%
|
$1,708,012
$311.48 P/Share
|
|
Dec 01
2023
|
Blair Williams Todt EVP, CLO & CAO |
SELL
Payment of exercise price or tax liability
|
Direct |
116
-0.92%
|
$56,028
$483.12 P/Share
|
|
Nov 30
2023
|
Ronald W Penczek CAO & Controller |
SELL
Open market or private sale
|
Direct |
1,055
-37.12%
|
$501,125
$475.17 P/Share
|
|
Nov 01
2023
|
Charles Morgan Kendrick Jr EVP & President, Commercial |
SELL
Payment of exercise price or tax liability
|
Direct |
79
-0.52%
|
$35,234
$446.66 P/Share
|
|
Nov 01
2023
|
Peter D Haytaian EVP & Pres Carelon & CarelonRx |
SELL
Payment of exercise price or tax liability
|
Direct |
154
-0.86%
|
$68,684
$446.66 P/Share
|
|
Oct 24
2023
|
Ronald W Penczek CAO & Controller |
SELL
Open market or private sale
|
Direct |
64
-2.2%
|
$29,056
$454.35 P/Share
|